<code id='C0518989A7'></code><style id='C0518989A7'></style>
    • <acronym id='C0518989A7'></acronym>
      <center id='C0518989A7'><center id='C0518989A7'><tfoot id='C0518989A7'></tfoot></center><abbr id='C0518989A7'><dir id='C0518989A7'><tfoot id='C0518989A7'></tfoot><noframes id='C0518989A7'>

    • <optgroup id='C0518989A7'><strike id='C0518989A7'><sup id='C0518989A7'></sup></strike><code id='C0518989A7'></code></optgroup>
        1. <b id='C0518989A7'><label id='C0518989A7'><select id='C0518989A7'><dt id='C0518989A7'><span id='C0518989A7'></span></dt></select></label></b><u id='C0518989A7'></u>
          <i id='C0518989A7'><strike id='C0518989A7'><tt id='C0518989A7'><pre id='C0518989A7'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:leisure time    - browse:92
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia